On September 5, 2017 Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, reported that a poster will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), being held in Madrid, Spain, Sept. 8-12, 2017 (Press release, Endocyte, SEP 5, 2017, View Source [SID1234520378]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation is as follows:
Abstract #: 793PD
Title: "Phase 1 Study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)"
When: Sunday, Sept. 10, 2017, from 9:15 – 10:30 AM CEST
Session Type: Poster Discussion Session
Title: Genitourinary tumours, prostate
Location: Bilbao Auditorium
About EC1169 and the Phase 1 Trial
EC1169 is an investigational therapeutic SMDC constructed of a high affinity PSMA-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, tubulysin B hydrazide (TubBH). Patient PSMA-status is determined using the investigational companion imaging agent, EC0652. EC1169 and EC0652 are currently being evaluated in a Phase 1b study in up to 50 taxane-exposed mCRPC patients at a maximum clinical EC1169 dose of 6.5 mg/m2. Endocyte has stopped enrollment of taxane-naïve mCRPC patients (ClinicalTrials.gov Identifier: NCT02202447).
The open-label, multicenter, non-randomized study is divided into two parts. The first part, phase 1a, of the study, now complete, was designed to determine the maximum clinical dose and recommended Phase 2 dose of EC1169 in patients with mCRPC.
Endocyte is currently enrolling the second part, phase 1b, of the study, which is designed to evaluate the safety and efficacy of EC1169 in taxane-exposed patients, with a primary study endpoint of radiographic progression free survival in patients selected as PSMA-positive. The trial is expected to complete enrollment in Q3 2017 with a more mature endpoint assessment by year-end.